Veeva Systems (NYSE:VEEV) Updates Q2 2027 Earnings Guidance

Veeva Systems (NYSE:VEEV) issued an update on its second quarter 2027 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.210-2.220 for the period, compared to the consensus earnings per share estimate of 2.070. The company issued revenue guidance of $902.0 million-$905.0 million, compared to the consensus revenue estimate of $887.5 million. Veeva Systems also updated its FY 2027 guidance to 9.050-9.050 EPS.

Veeva Systems Stock Performance

VEEV opened at $178.56 on Friday. Veeva Systems has a one year low of $148.05 and a one year high of $310.50. The stock’s fifty day moving average is $166.27 and its 200-day moving average is $195.90. The company has a market capitalization of $29.16 billion, a PE ratio of 31.83, a P/E/G ratio of 0.79 and a beta of 0.95.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. Veeva Systems had a return on equity of 13.89% and a net margin of 28.37%.The company had revenue of $882.95 million for the quarter, compared to the consensus estimate of $857.73 million. During the same quarter in the previous year, the business earned $1.97 EPS. The company’s quarterly revenue was up 16.3% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. On average, equities research analysts forecast that Veeva Systems will post 6.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VEEV has been the topic of a number of research reports. Truist Financial reissued a “buy” rating and issued a $262.00 price objective (down from $275.00) on shares of Veeva Systems in a research note on Thursday, March 5th. Oppenheimer reaffirmed an “outperform” rating and issued a $225.00 price target on shares of Veeva Systems in a report on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $340.00 price target on shares of Veeva Systems in a report on Thursday. BNP Paribas Exane reaffirmed an “outperform” rating and issued a $285.00 price target on shares of Veeva Systems in a report on Thursday. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of Veeva Systems in a report on Thursday. Eighteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Veeva Systems has a consensus rating of “Moderate Buy” and an average target price of $250.96.

Insider Transactions at Veeva Systems

In other Veeva Systems news, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $155.64, for a total transaction of $116,730.00. Following the sale, the director directly owned 3,253 shares of the company’s stock, valued at $506,296.92. The trade was a 18.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by company insiders.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva beat first-quarter estimates, with EPS of $2.24 and revenue of $882.9 million, while Q2 revenue guidance also came in above expectations, supporting the case for continued growth. Article Title
• Positive Sentiment: Management raised fiscal 2027 outlook and highlighted AI initiatives, including Falcon AI agents and new platform expansion, which could improve investor sentiment around product innovation and future monetization. Article Title
• Positive Sentiment: Several brokers remain constructive, with firms like Oppenheimer, RBC, Needham, BTIG, and Baird reiterating bullish ratings and high price targets, suggesting some analysts see meaningful upside despite the recent pullback.
• Neutral Sentiment: Other analysts turned more cautious, including Goldman Sachs, UBS, BMO, and Citigroup, which lowered price targets, adding to the mixed read-through from the earnings report.
• Negative Sentiment: Some commentary pointed to concerns about the legacy CRM business and customer migration dynamics, which may be tempering enthusiasm around the AI story and weighing on the shares.

Institutional Trading of Veeva Systems

Large investors have recently added to or reduced their stakes in the company. J.Safra Asset Management Corp raised its stake in Veeva Systems by 2,940.0% during the 4th quarter. J.Safra Asset Management Corp now owns 152 shares of the technology company’s stock valued at $34,000 after purchasing an additional 147 shares during the period. Raiffeisen Bank International AG raised its stake in Veeva Systems by 59.8% during the 4th quarter. Raiffeisen Bank International AG now owns 155 shares of the technology company’s stock valued at $35,000 after purchasing an additional 58 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of Veeva Systems in the third quarter worth $45,000. Rakuten Securities Inc. increased its stake in shares of Veeva Systems by 56.7% in the second quarter. Rakuten Securities Inc. now owns 163 shares of the technology company’s stock worth $47,000 after acquiring an additional 59 shares during the last quarter. Finally, Palisade Asset Management LLC acquired a new position in shares of Veeva Systems in the third quarter worth $66,000. 88.20% of the stock is owned by institutional investors and hedge funds.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.